Cargando…

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study

BACKGROUND: IBI362 (LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes. The aim of this randomised, placebo-controlled, multiple ascending dose phase 1b study was to evaluate the safety, tolera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Linong, Jiang, Hongwei, An, Pei, Deng, Huan, Liu, Meng, Li, Li, Feng, Liqi, Song, Baili, Han-Zhang, Han, Ma, Qingyang, Qian, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374649/ https://www.ncbi.nlm.nih.gov/pubmed/34430840 http://dx.doi.org/10.1016/j.eclinm.2021.101088

Ejemplares similares

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes
por: Jiang, Hongwei, et al.
Publicado: (2022)

ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity
por: Ji, Linong, et al.
Publicado: (2022)

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
por: Ji, Linong, et al.
Publicado: (2022)

Glucagon, GLP-1 and Thermogenesis
por: González-García, Ismael, et al.
Publicado: (2019)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Ibis
por: Vargas Vila, José María, 1860-1933
Publicado: (1908)

Allosteric Modulation of the Activity of the Glucagon-like Peptide-1 (GLP-1) Metabolite GLP-1 9–36 Amide at the GLP-1 Receptor
por: Li, Naichang, et al.
Publicado: (2012)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto's thyroiditis
por: Jin, Yue, et al.
Publicado: (2015)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Modulation of Cardiac Ventricular Excitability by GLP-1 (Glucagon-Like Peptide-1)
por: Ang, Richard, et al.
Publicado: (2018)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
por: Ørgaard, Anne, et al.
Publicado: (2017)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies
por: Desai, Amit, et al.
Publicado: (2020)

Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist
por: Kawai, Takahiro, et al.
Publicado: (2020)

Ultrastructural Study on Colocalization of Glucagon-Like Peptide (GLP)-1 with GLP-2 in Chicken Intestinal L-Cells
por: NISHIMURA, Kei, et al.
Publicado: (2013)

[Gly²]-GLP-2, But Not Glucagon or [D-Ala²]-GLP-1, Controls Collagen Crosslinking in Murine Osteoblast Cultures
por: Mieczkowska, Aleksandra, et al.
Publicado: (2021)

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
por: Unger, Jeffrey R., et al.
Publicado: (2011)

Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning
por: Basalay, Marina V., et al.
Publicado: (2016)

Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
por: Diz-Chaves, Yolanda, et al.
Publicado: (2020)

Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
por: Kalra, Sanjay, et al.
Publicado: (2021)

Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
por: Tanday, Neil, et al.
Publicado: (2021)

Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals
por: Model, Jorge F A, et al.
Publicado: (2022)

Taking Aim at Islet Hormones With GLP-1: Is Insulin or Glucagon the Better Target?
por: D'Alessio, David A.
Publicado: (2010)

Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection()()
por: Ussher, John R., et al.
Publicado: (2014)

The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain
por: Bae, Choon Sang, et al.
Publicado: (2017)

Pharmacokinetics and Safety of Cotadutide, a GLP-1 and Glucagon Receptor Dual Agonist, in Individuals with Renal Impairment: A Single-Dose, Phase I, Bridging Study
por: Klein, Gernot, et al.
Publicado: (2023)

Glucagon Acting at the GLP-1 Receptor Contributes to β-Cell Regeneration Induced by Glucagon Receptor Antagonism in Diabetic Mice
por: Wei, Tianjiao, et al.
Publicado: (2023)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First‐in‐Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose)
por: Parmar, Deven V., et al.
Publicado: (2022)

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
por: Lowe, Stephen Loucian, et al.
Publicado: (2021)

In Vitro and In Vivo Effects of Natural Putative Secretagogues of Glucagon-Like Peptide-1 (GLP-1)
por: Rafferty, Eamon P., et al.
Publicado: (2011)

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
por: Geloneze, Bruno, et al.
Publicado: (2017)

Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?
por: Basalay, Maryna V., et al.
Publicado: (2020)

Regulation of Human Sortilin Alternative Splicing by Glucagon-like Peptide-1 (GLP1) in Adipocytes
por: Lui, Ashley, et al.
Publicado: (2023)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
por: Hope, David C. D., et al.
Publicado: (2021)

Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake
por: Ouberai, Myriam M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_os9tgqkqvomrm6e1a35ufht7tt